Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab with Chemoradiation for HPV+ KRAS-Variant OPSCC
NCT04106362Phase 2Terminated
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Jan 2020
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of KL-140 in oropharyngeal squamous cell carcinoma (OPSCC), sponsored by UCLA Jonsson Comprehensive Cancer Center. Started Jan 2020; status: terminated.
02
Drugs
KL-140
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT04106362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04106362.